Axovant to Host First R&D Day March 29, 2019
February 21 2019 - 8:00AM
Axovant Sciences (NASDAQ: AXGT), a clinical-stage company
developing innovative gene therapies, today announced that it will
host its first R&D Day for investors and analysts in New York
City on Friday, March 29, 2019, beginning at 8:30 a.m. ET.
Axovant’s chief executive officer, Pavan
Cheruvu, MD, will provide opening remarks and Gavin Corcoran, MD,
executive vice president of R&D, will moderate the event. The
agenda for R&D Day will include development updates, scientific
and clinical insights from prominent physicians and researchers,
and patient perspectives across Axovant’s gene therapy pipeline.
Invited guest speakers for each program include:
AXO-Lenti-PD for Parkinson’s
disease
- C. Warren Olanow, MD, FRCPC, FRCP (hon), Mount Sinai School of
Medicine
- Stéphane Palfi, MD, PhD, Assistance Publique - Hôpitaux de
Paris
AXO-AAV-GM1 and AXO-AAV-GM2 for GM1
gangliosidosis, Tay-Sachs and Sandhoff diseases
- Terence Flotte, MD, University of Massachusetts Medical
School
- Heather Gray-Edwards, DVM, PhD, University of Massachusetts
Medical School
- Douglas Martin, PhD, Auburn University
AXO-AAV-OPMD for Oculopharyngeal
Muscular Dystrophy
- Guy Rouleau, OQ, MD, PhD, FRCP, FRSC, Montreal Neurological
Institute & Hospital
Axovant’s Scientific Advisory
Board
- Chairman, Michael Hayden, MB ChB, PhD, University of British
Columbia
The event will be webcast live under the
investor relations section of Axovant’s website at www.axovant.com.
An archived webcast will be available on Axovant’s website for 30
days following the event.
About Axovant
Axovant Sciences is a clinical-stage gene therapy company
focused on developing a pipeline of innovative product candidates
for debilitating neurological and neuromuscular diseases. The
company’s current pipeline of gene therapy candidates targets GM1
gangliosidosis, GM2 gangliosidosis (including Tay-Sachs disease and
Sandhoff disease), Parkinson’s disease, oculopharyngeal muscular
dystrophy (OPMD), amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia. Axovant is focused on accelerating product
candidates into and through clinical trials with a team of experts
in gene therapy development and through external partnerships with
leading gene therapy organizations. For more information, visit
www.axovant.com.
Contacts:
MediaMike BeyerSam Brown Inc.
(312) 961-2502mikebeyer@sambrown.commedia@axovant.com
InvestorsTricia
TruehartAxovant(631) 892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024